Wednesday, August 1, 2007

Researchers confirm colloidal silver safe and effective

The FDA and various anti-quack sites have been launching a campaign against the stuff for some time now. Now quackery is a terrible thing, and nothing to be defended. However as always, you are only being told half the story, and the facts are twisted to make it look like dangerous quackery.

Colloidal silver is a broad name for a solution containing ions of silver. So by this broad label water and silver nitrate would be considered silver colloid. Now what about water and pure 100% silver particles? Yes, it gets labeled the same thing.

Here in lies the deception and confusion.

Silver nitrate and water is a terribly toxic mixture.
Water and pure silver is completely safe, with no heavy metal toxicity.

Argyria occurs when consuming large amounts of toxic silver preparations. These toxic silver nitrate solutions can contain as much as 25 000 ppm.

Water and 100% silver is potent at 30 ppm, and has no toxic side effects.

A trial against Mycobacterium Avium Complex, or hot tub lung, showed it to be the most potent anti-mycobacterium known to man. It demonstrated excellent intracellular antibiotic properties and showed no heavy metal toxicity.
http://www.medicalnewstoday.com/articles/39637.php

Tuberculosis, Leprosy, Crohn’s Disease, MAC and so on should respond to treatment very rapidly.

The way to make the stuff is easy, anyone can do it. The hardest thing is believability.
http://video.google.ca/videoplay?docid=2095786730805958061&q=bob+beck&total=241&start=0&num=10&so=0&type=search&plindex=0

3 comments:

  1. Could you please tell me where this research is. It is not on the website
    that is sited.
    Thanks Nancy Appleton

    A trial against Mycobacterium Avium Complex, or hot tub lung, showed it to be the most potent anti-mycobacterium known to man. It demonstrated excellent intracellular antibiotic properties and showed no heavy metal toxicity.
    http://www.medicalnewstoday.com/articles/39637.php

    http://exploitationnation.blogspot.com/2007/08/researchers-confirm-colloidal-silver.html

    ReplyDelete
    Replies
    1. New treatment for 'hot tub lung'

      Klearsen Corp., a manufacturer of natural healthcare products, announced it has developed a therapy that may be significantly more effective than traditional methods currently used to treat mycobacterium avium complex (MAC).

      The new treatment, named Klearson Respiratory Inhalation Therapy, is believed to be the first non-antibiotic therapy designed to remedy the disease.

      "There is [currently] no good therapy specifically for treating MAC," said Steven Frank, chief technical officer at Klearsen in Boulder, Colo. "Based on the dramatic results we've been getting, it's hard to describe how important the therapy's impact will be on the treatment of this disease."

      Often called "hot tub lung," MAC is an infection and allergic reaction of the lungs due to exposure to m. avium, a myco-bacteria. Symptoms include shortness of breath, fatigue, wet cough, tightness in the chest and fever, according to the Mayo Clinic in Rochester, N.Y.

      The disease is not contagious and usually is contracted through exposure to wet environments such as hot tubs and indoor pools, which can provide ideal conditions for the growth of this type of bacteria.

      Chlorine, which is often used to treat pool and spa water, loses most of its disinfectant properties at water temperatures above 84 degrees Fahrenheit. Moreover, the bacteria sometimes is carried into the air on the aerosols produced by spa jets.


      Klearsen's new therapy is based on an antimicrobial compound, KC-287. The compound is a liquid agent that is turned into a fine mist and inhaled through a nebulizer, sort of like a nasal spray. The therapy is designed to coat the inside of the patient's lungs directly with the compound.

      Research into KC-287 began in 1999 as a way to treat tuberculosis, but was put on hold due to limited funds. Though the company suspected the formula might be effective in fighting m. avium, it wasn't until recently that it was able to perform those tests with the help of the National Jewish Medical and Research Center in Denver.

      Lab results showed that KC-287 attenuated bacterial loads five to 10 times faster than antibiotics. Recent clinical trials also pointed to substantial improvement in recovery times vs. antibiotic protocols.

      In one clinical trial conducted by Klearsen, a patient who suffered from hot tub lung for 12 years achieved results within the first three weeks of the therapy. The patient's production of sputum, a phlegm caused by MAC, had reached a negative sample. After two months, her symptoms had been virtually eliminated.

      "This is a very exciting period of demonstration for KC-287," said Chris Grout, Klearsen's vice president of marketing and sales. "We've all seen the dramatic capabilities of this product, and now it is finally reaching the surface where it can benefit huge portions of the population."

      The prevalence of hot tub lung is unknown. The National Centers for Disease Control and Prevention do not track the number of incidents or outbreaks. However, population-based data from Houston and a few other metropolitan areas suggest that one person in 100,000 contracts MAC each year.

      Though Klearsen's therapy was patented several years ago, the treatment has not yet received Food & Drug Administration approval.

      It looks like this discovery is fading under the rug, as with all discoveries that clash with the profits and agenda of the powers that be.

      Delete
    2. Klearsen Corporation has demonstrated in vitro that its antimicrobial compound KC-287 is more effective against non-tuberculous Mycobacterium avium and M. abscessus than any of the presently used antibiotics

      BOULDER, Colo., March 14 /PRNewswire/ -- Klearsen Corporation, a manufacturer of natural health care products, announced today that their KC- 287 antimicrobial compound was shown to be more effective against non- tuberculous M. avium and M. abscessus than any antibiotic presently in use to treat these conditions.

      The testing, performed at a National Research Center, utilized an automated screening protocol to measure the inhibitory effect of various drugs on mycobacteria. "After having very good results against M. tuberculosis, it seemed like the obvious step to screen the compound against M. avium and M. abscessus," said Steve Frank, the project director. "We have been utilizing this compound in our patented Respiratory Inhalation Therapy treatment for years to deal with numerous ailments and this testing finally provides us with the substantiation necessary to move into the mycobacteria treatment arena."

      Preliminary work with an MAC (Mycobacterium avium complex) patient in clinical trials has shown encouraging results and suggests that the treatment period for this condition could be reduced from a typical 12- to 16-month course of antibiotics to a 4-week course of the Klearsen Respiratory Inhalation Therapy. "This is a very exciting period of demonstration for our KC-287 antimicrobial compound," stated Chris Groutt, the Marketing Director. "We have all seen the dramatic capabilities of this product and now it is finally reaching the surface where it can benefit huge portions of the population."

      The treatment utilizes a nebulized mist of KC-287 to repeatedly coat the inner surfaces of the lungs. Being on the air-side of the tissue and formulated to gain enhanced entry into the bacterial cells allow the active agent to very effectively kill the mycobacteria with very low total dose to the subject. Although the treatment is still in the experimental stage, early results are so encouraging, that clinical studies are moving forward.

      Paul Whittle, the CEO of Klearsen Corp., is anxious to see this technology applied to MAC as well as tuberculosis patients: "Klearsen Corporation holds several patents relating to the respiratory therapy and the active agent. We are very pleased to see this level of performance in vivo."

      Klearsen Corporation can be reached at 303-443-8700. Some of the technical reports can be accessed on-line at http://www.klearsen.com/.

      Contact: Chris Groutt, Klearsen Corporation, 1-888-303-3388, Chrisg@klearsen.com

      This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.

      CONTACT: Chris Groutt of Klearsen Corporation, +1-888-303-3388, Chrisg@klearsen.com

      Web site: http://www.klearsen.com/

      I believe Klearsen no longer exists, I think they go by the name of Peaceful Mountain.
      I have been so busy, I must update this blog more often.

      Delete